TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01005563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef/Pork
Description: Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy/Legumes
Description: Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 24
Description: Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT02704637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Description: HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
Study: NCT00882375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine administered using novel NRT user instructions
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT00882375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered using novel NRT user instructions
Study: NCT01451840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine
Description: Administration of alkalinized lidocaine in the endotracheal tube cuff
Study: NCT01815840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib 150 mg hard gelatin capsule orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib 150 mg hard gelatin capsule orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vismodegib placebo orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vismodegib placebo orally once daily
Study: NCT01085877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol, 25 mcg
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, 25 mcg
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
Study: NCT01336413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active comparator, except placebo dispensed.
Study: NCT03781778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention (resistant starch)
Description: Eat foods with resistant starch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention (regular starch)
Description: Eat foods with regular corn starch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01832155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Description: Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hatha Yoga
Description: The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
Study: NCT01431053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: Aspirin 50mg po daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25mg po daily
Study: NCT00225498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziprasidone vs risperidone or olanzapine
Description: ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone vs risperidone or olanzapine
Description: ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
Study: NCT01957813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Health Services
Description: Peer education and health services
Study: NCT03139123

Intervention type: OTHER
Intervention: Hemodynamic monitoring during passive leg raising
Description: Measurement of hypotensive episodes related to preload dependance.
Study: NCT04679194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mana 312
Description: Mana 312 is a cellular product comprised of expanded T cells derived from allogeneic donor leukocytes that have been stimulated with monocyte derived dendritic cells pulsed with tumor-associated antigen (TAA) peptide mixes for 3 antigens: Wilms Tumor gene 1 (WT 1), the preferentially expressed antigen of melanoma (PRAME), and Survivin.~Each Mana 312 product is specifically matched for an individual subject and will be manufactured from leukocytes from the same donor who provided stem cells to that subject for their current allogeneic hematopoietic stem cell transplantation (HSCT).
Study: NCT03492606

Intervention type: PROCEDURE
Intervention: Samples
Description: lumbar puncture, blood and CSF samples, SNPs analysis
Study: NCT01000259

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Samples are analyzed in laboratory studies
Study: NCT00728091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets
Study: NCT01888224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin Capsules,40 mg
Study: NCT01222780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo
Description: Marqibo® intravenously (IV) over 60 minutes (+ 10 minutes) every 7 days (+ 3 days) for 4 consecutive weeks (day 1, 8, 15, 22) for a 28-day treatment cycle
Study: NCT03114332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcutaneous Drain
Description: A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
Study: NCT02914665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: 20 mg elamipretide administered intravenously once daily for 7 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously once daily for 7 consecutive days
Study: NCT00108316

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoxetine (Liquid Prozac)
Study: NCT01672424

Intervention type: OTHER
Intervention: Ice Chips
Description: 11 ounces of ice chips given to the laboring parturient

Intervention type: OTHER
Intervention: Protein Drink
Description: Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
Study: NCT02172378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation capsules
Study: NCT02861898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial Mannitol
Study: NCT01787578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sobetirome
Description: 50 mcg or 100 mcg once-daily oral
Study: NCT02608112

Intervention type: DRUG
Intervention: Methotrexate
Description: Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 30
Description: Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT01695044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
Study: NCT03556059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role of EOSS
Description: The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role of EOSS
Description: The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Role of EOSS
Description: The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
Study: NCT02274116

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM - Intermittent Room Air - room air mixture
Description: Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
Study: NCT01245699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
Description: scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
Study: NCT03444298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Tocopherol
Description: Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gamma Tocopherol
Description: Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
Study: NCT02278042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Consumption
Study: NCT02278042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Consumption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Consumption
Study: NCT00677807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Study: NCT03444298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each dose consists of two capsules by mouth once daily for a total of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each dose consists of two capsules by mouth once daily for a total of 7 days.
Study: NCT03458416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study: NCT02942771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.075mg/kg TT301/MW189
Description: 0.075 mg/kg IV twice daily on Days 1 through 5
Study: NCT03397342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP machine
Description: Use of CPAP machine during MRI
Study: NCT02546492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar gel
Description: Administration of the study drug in addition to the current maintenance immunosuppressive agents
Study: NCT02942771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15mg/kg TT301MW189
Description: 0.15 mg/kg IV twice daily on Days 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg/kg TT301/MW189
Description: 0.25 mg/kg IV twice daily on Days 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.30mg/kg TT301/MW189
Description: 0.30 mg/kg IV twice daily on Days 1 through 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 18
Description: Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 18
Description: Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 18
Description: Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 24
Description: Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT02423707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard Birch and/or 5-grasses
Description: 3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent
Description: This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 24
Description: Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT04114279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Performance of laparoscopic duodenal atresia repair
Description: completion of laparoscopic duodenal atresia repair in a surgical simulator
Study: NCT06200818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:CrYSGG

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Study: NCT01199302

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Administered intravenously once every 4 weeks
Study: NCT00318591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath
Description: hydrophilic coated urinary intermittent catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conveen Uncoated
Description: Uncoated urinary intermittent catheter
Study: NCT01184755

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRate
Study: NCT03754166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy
Description: Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom.